Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib in Preclinical Models of Uterine Cancer
March 30, 2020 08:00 ET
|
Aravive, Inc.
Inhibition of GAS6/AXL signaling induces ‘BRCAness’ in preclinical model of ovarian cancer, increasing response to platinum chemotherapy and PARP inhibitor Multiple Abstracts Published on Website of...
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
February 18, 2020 08:00 ET
|
Aravive, Inc.
Dose escalation of AVB-500 to 20mg/kg dose follows positive recommendation by independent Data Monitoring Committee review Plan to initiate Phase 2/3 study in Platinum Resistant Ovarian Cancer by...
Predictive Oncology Featured in Broadcast Evaluating Targeted Cancer Therapies, Higher Survival Rates
November 07, 2019 08:30 ET
|
Predictive Oncology
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Predictive Oncology (NASDAQ: POAI) announces the availability of a broadcast titled, “New Hope in the Battle Against Ovarian...
Predictive Oncology Featured in Publication Discussing the Impact of Artificial Intelligence on Cancer Treatment
November 06, 2019 08:30 ET
|
Predictive Oncology
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Predictive Oncology (NASDAQ: POAI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted...
Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer
November 05, 2019 08:00 ET
|
Celsion CORP
GEN-1 Manufacturing Technology Transfer Successfully Produces High-Quality Affordable Investigational Product for Use in Clinical Trials LAWRENCEVILLE, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) --...
Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer
October 29, 2019 19:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ADELAIDE, Australia, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) has today announced that Telix and AusHealth have entered into a collaboration...
Harpoon Therapeutics Announces Presentation on HPN328 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 22, 2019 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference
September 30, 2019 14:30 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief...
Aravive Presents Positive Data from Initial 12 Patients in Phase 1b Portion of its Phase 1b/2 Ovarian Cancer Study of AVB-500 in Late Breaking Oral Presentation at European Society for Medical Oncology Congress in Barcelona
September 27, 2019 10:15 ET
|
Aravive, Inc.
HOUSTON, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today presented positive data from the initial 12 patients of the ongoing Phase 1b portion of the company’s Phase 1b/2 study...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
August 28, 2019 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...